{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:08:19Z","timestamp":1792757299846,"version":"4.5.0"},"reference-count":274,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"DOI":"10.1038\/s41416-026-03572-1","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:06:28Z","timestamp":1787065588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Paediatric therapeutic development workshop on osteosarcoma"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2336-614X","authenticated-orcid":false,"given":"Joseph S.","family":"Baxter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Montiel Equihua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Berlanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Campbell-Hewson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro","family":"Cortes-Ciriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-6621","authenticated-orcid":false,"given":"Brian","family":"Crompton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Danielson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8356-5191","authenticated-orcid":false,"given":"Filemon","family":"Dela Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-1303","authenticated-orcid":false,"given":"Adrienne","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-2929","authenticated-orcid":false,"given":"Richard","family":"Gorlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian M.","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Hecker-Nolting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Helman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Kavanagh-Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2756-5813","authenticated-orcid":false,"given":"Pamela","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geffen","family":"Lass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ip-Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1337-3282","authenticated-orcid":false,"given":"J. Andrew","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Marchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-0707","authenticated-orcid":false,"given":"Martin G.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybille","family":"Mittnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Nathrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Palmerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-7835","authenticated-orcid":false,"given":"Pan","family":"Pantziarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-2465","authenticated-orcid":false,"given":"Damon","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Scotlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4463-5759","authenticated-orcid":false,"given":"Emily","family":"Slotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker","family":"Smallwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul H.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Wane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8738-5913","authenticated-orcid":false,"given":"Andrew D. J.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jenkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-8903","authenticated-orcid":false,"given":"Nathalie","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra J.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of LifeArc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Innovative Therapies for Children and Adolescents with Cancer (ITCC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cancer Research UK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Cancer Grand Challenge Protect team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"3572_CR1","unstructured":"WHO Blue Book. 2020 https:\/\/publications.iarc.who.int\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Soft-Tissue-And-Bone-Tumours-2020"},{"key":"3572_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, Gill J, Heymann D, Janeway KA, et al. Osteosarcoma. Nat Rev Dis Primers. 2022;8:77.","journal-title":"Nat Rev Dis Primers"},{"key":"3572_CR3","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/cancers14020360","volume":"14","author":"GA Odri","year":"2022","unstructured":"Odri GA, Tchicaya-Bouanga J, Yoon DJY, Modrowski D. Metastatic progression of osteosarcomas: a review of current knowledge of environmental versus oncogenic drivers. Cancers. 2022;14:360.","journal-title":"Cancers"},{"key":"3572_CR4","doi-asserted-by":"publisher","first-page":"e21206","DOI":"10.1097\/MD.0000000000021206","volume":"99","author":"Y Kaneuchi","year":"2020","unstructured":"Kaneuchi Y, Hakozaki M, Yamada H, Hasegawa O, Yamada S, Oka Y, et al. Very late relapse of high-grade osteosarcoma: a case report and review of the literature. Medicine. 2020;99:e21206.","journal-title":"Medicine"},{"key":"3572_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27444","volume":"66","author":"HL Spraker-Perlman","year":"2019","unstructured":"Spraker-Perlman HL, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Doski J, et al. Factors influencing survival after recurrence in osteosarcoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2019;66:e27444.","journal-title":"Pediatr Blood Cancer"},{"key":"3572_CR6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1200\/JCO.2002.20.3.776","volume":"20","author":"SS Bielack","year":"2002","unstructured":"Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776\u201390.","journal-title":"J Clin Oncol"},{"key":"3572_CR7","doi-asserted-by":"crossref","unstructured":"Montiel Equihua C, Molenaar JJ, Areso I, Biegel JA, Blanc P, Chi SN, et al. Paediatric therapeutic development workshop on rhabdoid tumours. Br J Cancer 2026;134:1510\u201328.","DOI":"10.1038\/s41416-026-03348-7"},{"key":"3572_CR8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/cncr.24121","volume":"115","author":"L Mirabello","year":"2009","unstructured":"Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531\u201343.","journal-title":"Cancer"},{"key":"3572_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejca.2018.11.027","volume":"109","author":"S Smeland","year":"2019","unstructured":"Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019;109:36\u201350.","journal-title":"Eur J Cancer"},{"key":"3572_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2106\/00004623-199403000-00007","volume":"76","author":"K Okada","year":"1994","unstructured":"Okada K, Frassica FJ, Sim FH, Beabout JW, Bond JR, Unni KK. Parosteal osteosarcoma. A clinicopathological study. J Bone Joint Surg Am. 1994;76:366\u201378.","journal-title":"J Bone Joint Surg Am"},{"key":"3572_CR11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1007\/s11999-008-0251-2","volume":"466","author":"JH Schwab","year":"2008","unstructured":"Schwab JH, Antonescu CR, Athanasian EA, Boland PJ, Healey JH, Morris CD. A comparison of intramedullary and juxtacortical low-grade osteogenic sarcoma. Clin Orthop Relat Res. 2008;466:1318\u201322.","journal-title":"Clin Orthop Relat Res"},{"key":"3572_CR12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/cncr.25718","volume":"117","author":"M Cesari","year":"2011","unstructured":"Cesari M, Alberghini M, Vanel D, Palmerini E, Staals EL, Longhi A, et al. Periosteal osteosarcoma: a single-institution experience. Cancer. 2011;117:1731\u20135.","journal-title":"Cancer"},{"key":"3572_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8631237","volume":"2018","author":"CM Chan","year":"2018","unstructured":"Chan CM, Lindsay AD, Spiguel ARV, Gibbs CP Jr., Scarborough MT. Periosteal Osteosarcoma: a Single-Institutional Study of Factors Related to Oncologic Outcomes. Sarcoma. 2018;2018:8631237.","journal-title":"Sarcoma"},{"key":"3572_CR14","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.ejca.2005.04.052","volume":"41","author":"RJ Grimer","year":"2005","unstructured":"Grimer RJ, Bielack S, Flege S, Cannon SR, Foleras G, Andreeff I, et al. Periosteal osteosarcoma\u2014a European review of outcome. Eur J Cancer. 2005;41:2806\u201311.","journal-title":"Eur J Cancer"},{"key":"3572_CR15","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1044::AID-CNCR6>3.0.CO;2-A","volume":"85","author":"K Okada","year":"1999","unstructured":"Okada K, Unni KK, Swee RG, Sim FH. High-grade surface osteosarcoma: a clinicopathologic study of 46 cases. Cancer. 1999;85:1044\u201354.","journal-title":"Cancer"},{"key":"3572_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2020.100288","volume":"23","author":"Z Deng","year":"2020","unstructured":"Deng Z, Huang Z, Ding Y, Su Y, Chan CM, Niu X. High-grade surface osteosarcoma: clinical features and oncologic outcome. J Bone Oncol. 2020;23:100288.","journal-title":"J Bone Oncol"},{"key":"3572_CR17","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0959-8049(02)00037-0","volume":"38","author":"EI Hauben","year":"2002","unstructured":"Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy, and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer. 2002;38:1218\u201325.","journal-title":"Eur J Cancer"},{"key":"3572_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/cncr.21724","volume":"106","author":"G Bacci","year":"2006","unstructured":"Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154\u201361.","journal-title":"Cancer"},{"key":"3572_CR19","first-page":"593","volume":"6","author":"JJ Liu","year":"2013","unstructured":"Liu JJ, Liu S, Wang JG, Zhu W, Hua YQ, Sun W, et al. Telangiectatic osteosarcoma: a review of the literature. Onco Targets Ther. 2013;6:593\u2013602.","journal-title":"Onco Targets Ther"},{"key":"3572_CR20","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2095::AID-CNCR6>3.0.CO;2-O","volume":"79","author":"H Nakajima","year":"1997","unstructured":"Nakajima H, Sim FH, Bond JR, Unni KK. Small cell osteosarcoma of bone. Review of 72 cases. Cancer. 1997;79:2095\u2013106.","journal-title":"Cancer"},{"key":"3572_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/764796","volume":"2012","author":"AM Malhas","year":"2012","unstructured":"Malhas AM, Sumathi VP, James SL, Menna C, Carter SR, Tillman RM, et al. Low-grade central osteosarcoma: a difficult condition to diagnose. Sarcoma. 2012;2012:764796.","journal-title":"Sarcoma"},{"key":"3572_CR22","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJM198709033171002","volume":"317","author":"MA Tucker","year":"1987","unstructured":"Tucker MA, D\u2019Angio GJ, Boice JD Jr., Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588\u201393.","journal-title":"N Engl J Med"},{"key":"3572_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3109\/03009730903177340","volume":"114","author":"A Okada","year":"2009","unstructured":"Okada A, Hatori M, Hosaka M, Watanuki M, Itoi E. Secondary osteosarcoma arising after treatment for childhood hematologic malignancies. Ups J Med Sci. 2009;114:249\u201355.","journal-title":"Ups J Med Sci"},{"key":"3572_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31344","volume":"71","author":"SS Bielack","year":"2024","unstructured":"Bielack SS, Mettmann V, Hecker-Nolting S, Borkhardt A, Hardes J, Kager L, et al. Osteosarcoma as a secondary malignancy following rhabdomyosarcoma: a report of 28 affected patients from the Cooperative Osteosarcoma Study Group (COSS). Pediatr Blood Cancer. 2024;71:e31344.","journal-title":"Pediatr Blood Cancer"},{"key":"3572_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34689-5","volume":"13","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Wang J, Sun M, Zuo D, Wang H, Shen J, et al. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment. Nat Commun. 2022;13:7207.","journal-title":"Nat Commun"},{"key":"3572_CR26","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3390\/cancers15072134","volume":"15","author":"S Southekal","year":"2023","unstructured":"Southekal S, Shakyawar SK, Bajpai P, Elkholy A, Manne U, Mishra NK, et al. Molecular subtyping and survival analysis of osteosarcoma reveals prognostic biomarkers and key canonical pathways. Cancers. 2023;15:2134.","journal-title":"Cancers"},{"key":"3572_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41413-022-00233-w","volume":"11","author":"H Zhang","year":"2023","unstructured":"Zhang H, Wang T, Gong H, Jiang R, Zhou W, Sun H, et al. A novel molecular classification method for osteosarcoma based on tumor cell differentiation trajectories. Bone Res. 2023;11:1.","journal-title":"Bone Res"},{"key":"3572_CR28","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1158\/2159-8290.CD-25-0237","volume":"16","author":"E L\u00f3pez-Fuentes","year":"2026","unstructured":"L\u00f3pez-Fuentes E, Clugston AS, Lee AG, Sayles LC, Sorensen N, Pons Ventura MV, et al. Epigenetic and transcriptional programs define osteosarcoma subtypes and establish targetable vulnerabilities. Cancer Discov. 2026;16:296\u2013319.","journal-title":"Cancer Discov"},{"key":"3572_CR29","doi-asserted-by":"crossref","unstructured":"Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A. Clinical targeted next-generation panel sequencing reveals MYC amplification is a poor prognostic factor in osteosarcoma. JCO Precis Oncol. 2023; 7:e2200334.","DOI":"10.1200\/PO.22.00334"},{"key":"3572_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70161","volume":"131","author":"MR Nagy","year":"2025","unstructured":"Nagy MR, Puopolo O, Alston E, Challa S, Ceca E, Li Y, et al. MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma. Cancer. 2025;131:e70161.","journal-title":"Cancer"},{"key":"3572_CR31","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1200\/JCO.2014.60.0734","volume":"33","author":"SS Bielack","year":"2015","unstructured":"Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279\u201387.","journal-title":"J Clin Oncol"},{"key":"3572_CR32","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.09.036","volume":"88","author":"N Gaspar","year":"2018","unstructured":"Gaspar N, Occean BV, Pacquement H, Bompas E, Bouvier C, Brisse HJ, et al. Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006\/sarcome-09 study. Eur J Cancer. 2018;88:57\u201366.","journal-title":"Eur J Cancer"},{"key":"3572_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ijc.32526","volume":"146","author":"S Piperno-Neumann","year":"2020","unstructured":"Piperno-Neumann S, Ray-Coquard I, Occean BV, Laurence V, Cupissol D, Perrin C, et al. Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006\/Sarcome-09 study. Int J Cancer. 2020;146:413\u201323.","journal-title":"Int J Cancer"},{"key":"3572_CR34","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-10-0284","volume":"16","author":"J Smida","year":"2010","unstructured":"Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res. 2010;16:4256\u201367.","journal-title":"Clin Cancer Res"},{"key":"3572_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71044","volume":"14","author":"E Tirtei","year":"2025","unstructured":"Tirtei E, Michelsen SW, Haveman LM, Meazza C, Oliveira JF, Rasool A, et al. Prognostic factors in newly diagnosed high-grade osteosarcoma\u2014a systematic review. Cancer Med. 2025;14:e71044.","journal-title":"Cancer Med"},{"key":"3572_CR36","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2015.65.5381","volume":"34","author":"JP Lagmay","year":"2016","unstructured":"Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O, et al. Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through Children\u2019s Cancer Group, Pediatric Oncology Group, and Children\u2019s Oncology Group: learning from the past to move forward. J Clin Oncol. 2016;34:3031\u20138.","journal-title":"J Clin Oncol"},{"key":"3572_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ejca.2022.05.035","volume":"172","author":"P Hingorani","year":"2022","unstructured":"Hingorani P, Krailo M, Buxton A, Hutson P, Sondel PM, Diccianni M, et al. Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: a report from the Children\u2019s Oncology Group. Eur J Cancer. 2022;172:264\u201375.","journal-title":"Eur J Cancer"},{"key":"3572_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102625","volume":"120","author":"R van Ewijk","year":"2023","unstructured":"van Ewijk R, Cleirec M, Herold N, le Deley MC, van Eijkelenburg N, Boudou-Rouquette P, et al. A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: can we inform future trial design? Cancer Treat Rev. 2023;120. 102625.","journal-title":"Cancer Treat Rev"},{"key":"3572_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100250","volume":"6","author":"N Gaspar","year":"2021","unstructured":"Gaspar N, Campbell-Hewson Q, Gallego Melcon S, Locatelli F, Venkatramani R, Hecker-Nolting S, et al. Phase I\/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050). ESMO Open. 2021;6:100250.","journal-title":"ESMO Open"},{"key":"3572_CR40","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","volume":"20","author":"F Duffaud","year":"2019","unstructured":"Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, Penel N, Bompas E, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20:120\u201333.","journal-title":"Lancet Oncol"},{"key":"3572_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","volume":"21","author":"A Italiano","year":"2020","unstructured":"Italiano A, Mir O, Mathoulin-Pelissier S, Penel N, Piperno-Neumann S, Bompas E, et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:446\u201355.","journal-title":"Lancet Oncol"},{"key":"3572_CR42","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1200\/JCO.18.02374","volume":"37","author":"LE Davis","year":"2019","unstructured":"Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37:1424\u201331.","journal-title":"J Clin Oncol"},{"key":"3572_CR43","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jamaoncol.2024.4381","volume":"10","author":"N Gaspar","year":"2024","unstructured":"Gaspar N, Hung GY, Strauss SJ, Campbell-Hewson Q, Dela Cruz FS, Glade Bender JL. et a. Lenvatinib plus ifosfamide and etoposide in children and young adults with relapsed osteosarcoma: a phase 2 randomized clinical trial. JAMA Oncol. 2024;10:1645\u201353.","journal-title":"JAMA Oncol"},{"key":"3572_CR44","doi-asserted-by":"crossref","unstructured":"Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone. 2014;62:56\u201363.","DOI":"10.1016\/j.bone.2014.02.003"},{"key":"3572_CR45","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/path.2603","volume":"219","author":"AB Mohseny","year":"2009","unstructured":"Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219:294\u2013305.","journal-title":"J Pathol"},{"key":"3572_CR46","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1093\/carcin\/bgp180","volume":"30","author":"PP Lin","year":"2009","unstructured":"Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009;30:1789\u201395.","journal-title":"Carcinogenesis"},{"key":"3572_CR47","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1083\/jcb.200508130","volume":"172","author":"CJ Lengner","year":"2006","unstructured":"Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE, et al. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol. 2006;172:909\u201321.","journal-title":"J Cell Biol"},{"key":"3572_CR48","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrendo.2017.16","volume":"13","author":"DM Gianferante","year":"2017","unstructured":"Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13:480\u201391.","journal-title":"Nat Rev Endocrinol"},{"key":"3572_CR49","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1101\/gad.1656808","volume":"22","author":"CR Walkley","year":"2008","unstructured":"Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008;22:1662\u201376.","journal-title":"Genes Dev"},{"key":"3572_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","volume":"7","author":"X Chen","year":"2014","unstructured":"Chen X, Bahrami A, Pappo A, Easton J, Dalton J, Hedlund E, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7:104\u201312.","journal-title":"Cell Rep"},{"key":"3572_CR51","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/annonc\/mdw009","volume":"27","author":"M Bousquet","year":"2016","unstructured":"Bousquet M, Noirot C, Accadbled F, Sales de Gauzy J, Castex MP, Brousset P, et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann Oncol. 2016;27:738\u201344.","journal-title":"Ann Oncol"},{"key":"3572_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/dna.2006.0505","volume":"26","author":"M Kansara","year":"2007","unstructured":"Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 2007;26:1\u201318.","journal-title":"DNA Cell Biol"},{"key":"3572_CR53","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ijc.20269","volume":"111","author":"K Nishijo","year":"2004","unstructured":"Nishijo K, Nakayama T, Aoyama T, Okamoto T, Ishibe T, Yasura K, et al. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer. 2004;111:367\u201372.","journal-title":"Int J Cancer"},{"key":"3572_CR54","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151583","volume":"7","author":"S Bartholf DeWitt","year":"2022","unstructured":"Bartholf DeWitt S, Hoskinson Plumlee S, Brighton HE, Sivaraj D, Martz EJ, Zand M, et al. Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-\u03baB signaling and integrin binding. JCI insight. 2022;7:e151583.","journal-title":"JCI insight"},{"key":"3572_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0165-4608(02)00929-9","volume":"144","author":"K Al-Romaih","year":"2003","unstructured":"Al-Romaih K, Bayani J, Vorobyova J, Karaskova J, Park PC, Zielenska M, et al. Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genet Cytogenet. 2003;144:91\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"3572_CR56","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/627254","volume":"2012","author":"JW Martin","year":"2012","unstructured":"Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma. Sarcoma. 2012;2012:627254.","journal-title":"Sarcoma"},{"key":"3572_CR57","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","volume":"9","author":"LC Sayles","year":"2019","unstructured":"Sayles LC, Breese MR, Koehne AL, Leung SG, Lee AG, Liu HY, et al. Genome-informed targeted therapy for osteosarcoma. Cancer Discov. 2019;9:46\u201363.","journal-title":"Cancer Discov"},{"key":"3572_CR58","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.23782","volume":"113","author":"SS Freeman","year":"2008","unstructured":"Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 2008;113:1453\u201361.","journal-title":"Cancer"},{"key":"3572_CR59","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cell.2024.12.005","volume":"188","author":"J Espejo Valle-Inclan","year":"2025","unstructured":"Espejo Valle-Inclan J, De Noon S, Trevers K, Elrick H, van Belzen I, Zumalave S, et al. Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution. Cell. 2025;188:352\u201370.e22.","journal-title":"Cell"},{"key":"3572_CR60","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"CC Wu","year":"2020","unstructured":"Wu CC, Beird HC, Andrew Livingston J, Advani S, Mitra A, Cao S, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11:1008.","journal-title":"Nat Commun"},{"key":"3572_CR61","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.3390\/cells12121595","volume":"12","author":"L Twenhafel","year":"2023","unstructured":"Twenhafel L, Moreno D, Punt T, Kinney M, Ryznar R. Epigenetic changes associated with osteosarcoma: a comprehensive review. Cells. 2023;12:1595.","journal-title":"Cells"},{"key":"3572_CR62","doi-asserted-by":"publisher","first-page":"518","DOI":"10.4161\/cc.10.3.14756","volume":"10","author":"B Moolmuang","year":"2011","unstructured":"Moolmuang B, Tainsky MA. CREG1 enhances p16(INK4a) -induced cellular senescence. Cell Cycle. 2011;10:518\u201330.","journal-title":"Cell Cycle"},{"key":"3572_CR63","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.blo.0000188063.56091.69","volume":"442","author":"JH Oh","year":"2006","unstructured":"Oh JH, Kim HS, Kim HH, Kim WH, Lee SH. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin Orthop Relat Res. 2006;442:216\u201322.","journal-title":"Clin Orthop Relat Res"},{"key":"3572_CR64","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1038\/sj.onc.1205446","volume":"21","author":"K Harada","year":"2002","unstructured":"Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 2002;21:4345\u20139.","journal-title":"Oncogene"},{"key":"3572_CR65","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1002\/cncr.21762","volume":"106","author":"P Hou","year":"2006","unstructured":"Hou P, Ji M, Yang B, Chen Z, Qiu J, Shi X, et al. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer. 2006;106:1602\u20139.","journal-title":"Cancer"},{"key":"3572_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115472","volume":"210","author":"SL Chang","year":"2023","unstructured":"Chang SL, Lee CW, Yang CY, Lin ZC, Peng KT, Liu SC, et al. IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation. Biochem Pharmacol. 2023;210:115472.","journal-title":"Biochem Pharmacol"},{"key":"3572_CR67","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.7150\/thno.53347","volume":"11","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Li F, Gao B, Ma M, Chen M, Wu Y, et al. KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma. Theranostics. 2021;11:3868\u201381.","journal-title":"Theranostics"},{"key":"3572_CR68","doi-asserted-by":"publisher","first-page":"6154","DOI":"10.1111\/jcmm.14497","volume":"23","author":"X Shi","year":"2019","unstructured":"Shi X, Fan M. Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis. J Cell Mol Med. 2019;23:6154\u201363.","journal-title":"J Cell Mol Med"},{"key":"3572_CR69","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bbrc.2013.02.083","volume":"433","author":"JP Li","year":"2013","unstructured":"Li JP, Liu LH, Li J, Chen Y, Jiang XW, Ouyang YR, et al. Microarray expression profile of long noncoding RNAs in human osteosarcoma. Biochem Biophys Res Commun. 2013;433:200\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"3572_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23587","volume":"35","author":"C Xun","year":"2021","unstructured":"Xun C, Jiang D, Tian Z, Yunus A, Chen J. Long noncoding RNA plasmacytoma variant translocation gene 1 promotes epithelial-mesenchymal transition in osteosarcoma. J Clin Lab Anal. 2021;35:e23587.","journal-title":"J Clin Lab Anal"},{"key":"3572_CR71","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1158\/0008-5472.CAN-09-1902","volume":"70","author":"I Pasic","year":"2010","unstructured":"Pasic I, Shlien A, Durbin AD, Stavropoulos DJ, Baskin B, Ray PN, et al. Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene at chromosome 3q13.31 in osteosarcoma. Can Res. 2010;70:160\u201371.","journal-title":"Can Res"},{"key":"3572_CR72","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/15592294.2021.1890873","volume":"17","author":"X Zi","year":"2022","unstructured":"Zi X, Zhang G, Qiu S. Up-regulation of LINC00619 promotes apoptosis and inhibits proliferation, migration and invasion while promoting apoptosis of osteosarcoma cells through inactivation of the HGF-mediated PI3K-Akt signalling pathway. Epigenetics. 2022;17:147\u201360.","journal-title":"Epigenetics"},{"key":"3572_CR73","doi-asserted-by":"publisher","first-page":"E5564","DOI":"10.1073\/pnas.1419260111","volume":"111","author":"JA Perry","year":"2014","unstructured":"Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, et al. Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA. 2014;111:E5564\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3572_CR74","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/cncr.26617","volume":"118","author":"E Choy","year":"2012","unstructured":"Choy E, Hornicek F, MacConaill L, Harmon D, Tariq Z, Garraway L, et al. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. 2012;118:2905\u201314.","journal-title":"Cancer"},{"key":"3572_CR75","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cca.2014.12.041","volume":"444","author":"J Zhang","year":"2015","unstructured":"Zhang J, Yu XH, Yan YG, Wang C, Wang WJ. PI3K\/Akt signaling in osteosarcoma. Clin Chim Acta. 2015;444:182\u201392.","journal-title":"Clin Chim Acta"},{"key":"3572_CR76","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12974","volume":"54","author":"Y Liu","year":"2021","unstructured":"Liu Y, Liao S, Bennett S, Tang H, Song D, Wood D, et al. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 2021;54:e12974.","journal-title":"Cell Prolif"},{"key":"3572_CR77","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-3-030-43085-6_9","volume":"1258","author":"EM Greenfield","year":"2020","unstructured":"Greenfield EM, Collier CD, Getty PJ. Receptor tyrosine kinases in osteosarcoma: 2019 update. Adv Exp Med Biol. 2020;1258:141\u201355.","journal-title":"Adv Exp Med Biol"},{"key":"3572_CR78","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrc3838","volume":"14","author":"M Kansara","year":"2014","unstructured":"Kansara M, Teng MW, Smyth MJ, Thomas DM. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14:722\u201335.","journal-title":"Nat Rev Cancer"},{"key":"3572_CR79","doi-asserted-by":"publisher","first-page":"8939","DOI":"10.1007\/s13277-014-2165-9","volume":"35","author":"Y Liu","year":"2014","unstructured":"Liu Y, Ma YH, Sun ZZ, Rui YJ, Yin QD, Song S, et al. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumour Biol. 2014;35:8939\u201343.","journal-title":"Tumour Biol"},{"key":"3572_CR80","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13277-013-1019-1","volume":"35","author":"XW Yu","year":"2014","unstructured":"Yu XW, Wu TY, Yi X, Ren WP, Zhou ZB, Sun YQ, et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 2014;35:155\u201360.","journal-title":"Tumour Biol"},{"key":"3572_CR81","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/jcm5110096","volume":"5","author":"A Lamora","year":"2016","unstructured":"Lamora A, Talbot J, Mullard M, Brounais-Le Royer B, Redini F, Verrecchia F. TGF-\u03b2 signaling in bone remodeling and osteosarcoma progression. J Clin Med. 2016;5:96.","journal-title":"J Clin Med"},{"key":"3572_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-5","volume":"9","author":"M Hirotsu","year":"2010","unstructured":"Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, et al. Smoothened as a new therapeutic target for human osteosarcoma. Mol Cancer. 2010;9:5.","journal-title":"Mol Cancer"},{"key":"3572_CR83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/path.2880","volume":"224","author":"H Nagao","year":"2011","unstructured":"Nagao H, Ijiri K, Hirotsu M, Ishidou Y, Yamamoto T, Nagano S, et al. Role of GLI2 in the growth of human osteosarcoma. J Pathol. 2011;224:169\u201379.","journal-title":"J Pathol"},{"key":"3572_CR84","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/hmg\/ddp057","volume":"18","author":"F Engin","year":"2009","unstructured":"Engin F, Bertin T, Ma O, Jiang MM, Wang L, Sutton RE, et al. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum Mol Genet. 2009;18:1464\u201370.","journal-title":"Hum Mol Genet"},{"key":"3572_CR85","doi-asserted-by":"crossref","unstructured":"Lu Y, Guan GF, Chen J, Hu B, Sun C, Ma Q, et al. Aberrant CXCR4 and \u03b2-catenin expression in osteosarcoma correlates with patient survival. Oncol Lett. 2015;10:2123-9.","DOI":"10.3892\/ol.2015.3535"},{"key":"3572_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-450","volume":"14","author":"X Du","year":"2014","unstructured":"Du X, Yang J, Yang D, Tian W, Zhu Z. The genetic basis for inactivation of Wnt pathway in human osteosarcoma. BMC Cancer. 2014;14:450.","journal-title":"BMC Cancer"},{"key":"3572_CR87","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2012.12.118","volume":"431","author":"Y Ma","year":"2013","unstructured":"Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, et al. Inhibition of the Wnt-\u03b2-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun. 2013;431:274\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"3572_CR88","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/path.2628","volume":"220","author":"Y Cai","year":"2010","unstructured":"Cai Y, Mohseny AB, Karperien M, Hogendoorn PC, Zhou G, Cleton-Jansen AM. Inactive Wnt\/beta-catenin pathway in conventional high-grade osteosarcoma. J Pathol. 2010;220:24\u201333.","journal-title":"J Pathol"},{"key":"3572_CR89","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/labinvest.2011.72","volume":"91","author":"AB Mohseny","year":"2011","unstructured":"Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Investig. 2011;91:1195\u2013205.","journal-title":"Lab Investig"},{"key":"3572_CR90","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1038\/bjc.2013.549","volume":"109","author":"SU Lauvrak","year":"2013","unstructured":"Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Naml\u00f8s HM, Meza-Zepeda LA, et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer. 2013;109:2228\u201336.","journal-title":"Br J Cancer"},{"key":"3572_CR91","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1158\/1078-0432.CCR-23-0873","volume":"30","author":"CR Schott","year":"2024","unstructured":"Schott CR, Koehne AL, Sayles LC, Young EP, Luck C, Yu K, et al. Osteosarcoma PDX-derived cell line models for preclinical drug evaluation demonstrate metastasis inhibition by dinaciclib through a genome-targeted approach. Clin Cancer Res. 2024;30:849\u201364.","journal-title":"Clin Cancer Res"},{"key":"3572_CR92","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/03009858221083038","volume":"59","author":"J Beck","year":"2022","unstructured":"Beck J, Ren L, Huang S, Berger E, Bardales K, Mannheimer J, et al. Canine and murine models of osteosarcoma. Vet Pathol. 2022;59:399\u2013414.","journal-title":"Vet Pathol"},{"key":"3572_CR93","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/pbc.21078","volume":"49","author":"PJ Houghton","year":"2007","unstructured":"Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer. 2007;49:928\u201340.","journal-title":"Pediatr Blood Cancer"},{"key":"3572_CR94","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1007\/s11999.0000000000000291","volume":"476","author":"C Maloney","year":"2018","unstructured":"Maloney C, Edelman MC, Kallis MP, Soffer SZ, Symons M, Steinberg BM. Intratibial injection causes direct pulmonary seeding of osteosarcoma cells and is not a spontaneous model of metastasis: a mouse osteosarcoma model. Clin Orthop Relat Res. 2018;476:1514\u201322.","journal-title":"Clin Orthop Relat Res"},{"key":"3572_CR95","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","volume":"22","author":"HH Luu","year":"2005","unstructured":"Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis. 2005;22:319\u201329.","journal-title":"Clin Exp Metastasis"},{"key":"3572_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166063","volume":"13","author":"MEM da Costa","year":"2023","unstructured":"da Costa MEM, Droit R, Khneisser P, Gomez-Brouchet A, Adam-de-Beaumais T, et al. Longitudinal characterization of primary osteosarcoma and derived subcutaneous and orthotopic relapsed patient-derived xenograft models. Front Oncol. 2023;13:1166063.","journal-title":"Front Oncol."},{"key":"3572_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691741","volume":"12","author":"LJ Talbot","year":"2021","unstructured":"Talbot LJ, Chabot A, Funk A, Nguyen P, Wagner J, Ross A, et al. A novel orthotopic implantation technique for osteosarcoma of produces spontaneous metastases and illustrates dose-dependent efficacy B7-H3-CAR T cells. Front Immunol. 2021;12:691741.","journal-title":"Front Immunol"},{"key":"3572_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12361-z","volume":"24","author":"M Yao","year":"2024","unstructured":"Yao M, Lei Z, Peng F, Wang D, Li M, Zhong G, et al. Establishment of orthotopic osteosarcoma animal models in immunocompetent rats through muti-rounds of in-vivo selection. BMC Cancer. 2024;24:703.","journal-title":"BMC Cancer"},{"key":"3572_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.19","volume":"5","author":"A Saalfrank","year":"2016","unstructured":"Saalfrank A, Janssen KP, Ravon M, Flisikowski K, Eser S, Steiger K, et al. A porcine model of osteosarcoma. Oncogenesis. 2016;5:e210.","journal-title":"Oncogenesis"},{"key":"3572_CR100","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/0300985811398252","volume":"49","author":"AM Kavirayani","year":"2012","unstructured":"Kavirayani AM, Sundberg JP, Foreman O. Primary neoplasms of bones in mice: retrospective study and review of literature. Vet Pathol. 2012;49:182\u2013205.","journal-title":"Vet Pathol"},{"key":"3572_CR101","first-page":"80","volume":"188","author":"DL Gustafson","year":"2018","unstructured":"Gustafson DL, Duval DL, Regan DP, Thamm DH. Canine sarcomas as a surrogate for the human disease. Clin Pharmacol Ther. 2018;188:80\u201396.","journal-title":"Clin Pharmacol Ther"},{"key":"3572_CR102","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/0300985815574006","volume":"52","author":"E Nagamine","year":"2015","unstructured":"Nagamine E, Hirayama K, Matsuda K, Okamoto M, Ohmachi T, Kadosawa T, et al. Diversity of histologic patterns and expression of cytoskeletal proteins in canine skeletal osteosarcoma. Vet Pathol. 2015;52:977\u201384.","journal-title":"Vet Pathol"},{"key":"3572_CR103","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1158\/1078-0432.CCR-24-1854","volume":"30","author":"S Patkar","year":"2024","unstructured":"Patkar S, Mannheimer J, Harmon SA, Ramirez CJ, Mazcko CN, Choyke PL, et al. Large-scale comparative analysis of canine and human osteosarcomas uncovers conserved clinically relevant tumor microenvironment subtypes. Clin Cancer Res. 2024;30:5630\u201342.","journal-title":"Clin Cancer Res"},{"key":"3572_CR104","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","volume":"22","author":"NJ Mason","year":"2016","unstructured":"Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, et al. Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22:4380\u201390.","journal-title":"Clin Cancer Res"},{"key":"3572_CR105","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/vms3.1000","volume":"9","author":"AA Smith","year":"2023","unstructured":"Smith AA, Lindley SES, Almond GT, Bergman NS, Matz BM, Smith AN. Evaluation of zoledronate for the treatment of canine stage III osteosarcoma: a phase II study. Vet Med Sci. 2023;9:59\u201367.","journal-title":"Vet Med Sci"},{"key":"3572_CR106","doi-asserted-by":"publisher","first-page":"e004493","DOI":"10.1136\/jitc-2022-004493","volume":"10","author":"RB Rebhun","year":"2022","unstructured":"Rebhun RB, York D, Cruz SM, Judge SJ, Razmara AM, Farley LE, et al. Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response. J Immunother Cancer. 2022;10:e004493.","journal-title":"J Immunother Cancer"},{"key":"3572_CR107","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","volume":"78","author":"JW Purcell","year":"2018","unstructured":"Purcell JW, Tanlimco SG, Hickson J, Fox M, Sho M, Durkin L, et al. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res. 2018;78:4059\u201372.","journal-title":"Cancer Res"},{"key":"3572_CR108","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S0016-5107(73)73985-7","volume":"19","author":"AD Shiff","year":"1973","unstructured":"Shiff AD, Sheahan DG, Schwartz SS. Nodular lymphoid hyperplasia in a defunctionalized colon. Gastrointest Endosc. 1973;19:144\u20135.","journal-title":"Gastrointest Endosc"},{"key":"3572_CR109","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jid.2024.06.1279","volume":"145","author":"H Zhu","year":"2025","unstructured":"Zhu H, Meng M, Luo H, Distler JHW. The dual roles of leucine-rich repeat-containing protein 15 positive fibroblasts: from cancer to tissue repair. J Clin Investig Dermatol. 2025;145:200\u20134.e2.","journal-title":"J Clin Investig Dermatol"},{"key":"3572_CR110","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13287-018-0809-1","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Liu Y, Zhang M, Lv L, Zhang X, Zhang P, et al. LRRC15 promotes osteogenic differentiation of mesenchymal stem cells by modulating p65 cytoplasmic\/nuclear translocation. Stem Cell Res Ther. 2018;9:65.","journal-title":"Stem Cell Res Ther"},{"key":"3572_CR111","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/1535-7163.MCT-20-0406","volume":"20","author":"P Hingorani","year":"2021","unstructured":"Hingorani P, Roth ME, Wang Y, Zhang W, Gill JB, Harrison DJ, et al. ABBV-085, antibody-drug conjugate targeting LRRC15, is effective in osteosarcoma: a report by the Pediatric Preclinical Testing Consortium. Mol Cancer Ther. 2021;20:535\u201340.","journal-title":"Mol Cancer Ther"},{"key":"3572_CR112","doi-asserted-by":"publisher","unstructured":"O\u2019Reilly C, Tuladhar S, Nguyen P, et al. LRRC15-CAR T cells for the treatment of osteosarcoma. Clin Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2335","DOI":"10.1158\/1078-0432.CCR-24-2335"},{"key":"3572_CR113","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47649-y","volume":"15","author":"TI Shaw","year":"2024","unstructured":"Shaw TI, Wagner J, Tian L, Wickman E, Poudel S, Wang J, et al. Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression. Nat Commun. 2024;15:3732.","journal-title":"Nat Commun"},{"key":"3572_CR114","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611:148\u201354.","journal-title":"Nature"},{"key":"3572_CR115","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1002\/jor.24848","volume":"38","author":"J Cui","year":"2020","unstructured":"Cui J, Dean D, Wei R, Hornicek FJ, Ulmert D, Duan Z. Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. J Orthop Res. 2020;38:2362\u201372.","journal-title":"J Orthop Res"},{"key":"3572_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28771","volume":"68","author":"KK Slemmons","year":"2021","unstructured":"Slemmons KK, Mukherjee S, Meltzer P, Purcell JW, Helman LJ. LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. Pediatr Blood Cancer. 2021;68:e28771.","journal-title":"Pediatr Blood Cancer"},{"key":"3572_CR117","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri GD, Luke JJ, Hollebecque A, Powderly JD 2nd, Spira AI, et al. First in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin Cancer Res. 2021;27:3556\u201366.","journal-title":"Clin Cancer Res"},{"key":"3572_CR118","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41392-025-02410-9","volume":"10","author":"CM Storey","year":"2025","unstructured":"Storey CM, Altai M, L\u00fcckerath K, Zedan W, Zhu H, Breuer L, et al. Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance. Signal Transduct Target Ther. 2025;10:319.","journal-title":"Signal Transduct Target Ther"},{"key":"3572_CR119","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1158\/1535-7163.MCT-21-0836","volume":"21","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P, et al. Comprehensive surfaceome profiling to identify and validate novel cell-surface targets in osteosarcoma. Mol Cancer Ther. 2022;21:903\u201313.","journal-title":"Mol Cancer Ther"},{"key":"3572_CR120","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1158\/1535-7163.MCT-25-0437","volume":"25","author":"CM Burke","year":"2026","unstructured":"Burke CM, Feinberg TY, Brosius S, Bhanot UK, Jain M, Linkov I, et al. Antitumor activity of trastuzumab deruxtecan in pediatric solid tumors with variable HER2 expression. Mol Cancer Ther. 2026;25:156\u201367.","journal-title":"Mol Cancer Ther"},{"key":"3572_CR121","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1126\/science.1161233","volume":"322","author":"T Yusufzai","year":"2008","unstructured":"Yusufzai T, Kadonaga JT. HARP is an ATP-driven annealing helicase. Science. 2008;322:748\u201350.","journal-title":"Science"},{"key":"3572_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/srep17910","volume":"5","author":"T Sharma","year":"2015","unstructured":"Sharma T, Bansal R, Haokip DT, Goel I, Muthuswami R. SMARCAL1 negatively regulates C-Myc transcription by altering the conformation of the promoter region. Sci Rep. 2015;5:17910.","journal-title":"Sci Rep"},{"key":"3572_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/srep20532","volume":"6","author":"DT Haokip","year":"2026","unstructured":"Haokip DT, Goel I, Arya V, Sharma T, Kumari R, Priya R, et al. Transcriptional regulation of Atp-dependent chromatin remodeling factors: Smarcal1 and Brg1 mutually co-regulate each other. Sci Rep. 2026;6:20532.","journal-title":"Sci Rep"},{"key":"3572_CR124","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1101\/gad.1831509","volume":"23","author":"T Yusufzai","year":"2009","unstructured":"Yusufzai T, Kong X, Yokomori K, Kadonaga JT. The annealing helicase HARP is recruited to DNA repair sites via an interaction with RPA. Genes Dev. 2009;23:2400\u20134.","journal-title":"Genes Dev"},{"key":"3572_CR125","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1101\/gad.1832309","volume":"23","author":"A Ciccia","year":"2009","unstructured":"Ciccia A, Bredemeyer AL, Sowa ME, Terret ME, Jallepalli PV, Harper JW, et al. The SIOD disorder protein SMARCAL1 is an RPA-interacting protein involved in replication fork restart. Genes Dev. 2009;23:2415\u201325.","journal-title":"Genes Dev"},{"key":"3572_CR126","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.1074\/jbc.275.11.7648","volume":"275","author":"R Muthuswami","year":"2000","unstructured":"Muthuswami R, Truman PA, Mesner LD, Hockensmith JW. A eukaryotic SWI2\/SNF2 domain, an exquisite detector of double-stranded to single-stranded DNA transition elements. J Biol Chem. 2000;275:7648\u201355.","journal-title":"J Biol Chem"},{"key":"3572_CR127","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1101\/gad.1839909","volume":"23","author":"CE Bansbach","year":"2009","unstructured":"Bansbach CE, B\u00e9tous R, Lovejoy CA, Glick GG, Cortez D. The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks. Genes Dev. 2009;23:2405\u201314.","journal-title":"Genes Dev"},{"key":"3572_CR128","doi-asserted-by":"crossref","unstructured":"Tsherniak A, Vazquez F, Montgomery PG, Weir BA, Kryukov G, Cowley GS, et al. Defining a cancer dependency map. Cell. 2017;170:564\u201376.e16.","DOI":"10.1016\/j.cell.2017.06.010"},{"key":"3572_CR129","unstructured":"DEPMAP Portal. https:\/\/depmap.org\/portal\/."},{"key":"3572_CR130","doi-asserted-by":"crossref","unstructured":"Brown A, Strickland LM, Erman EN, Pirozzi CJ, Low JT, Diplas BH, et al. SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of Telomeres. Neuro Oncol. 2026:noaf300.","DOI":"10.1093\/neuonc\/noaf300"},{"key":"3572_CR131","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1016\/j.febslet.2010.06.009","volume":"584","author":"JD Henson","year":"2010","unstructured":"Henson JD, Reddel RR. Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett. 2010;584:3800\u201311.","journal-title":"FEBS Lett"},{"key":"3572_CR132","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1038\/sj.onc.1204493","volume":"20","author":"C Scheel","year":"2001","unstructured":"Scheel C, Schaefer KL, Jauch A, Keller M, Wai D, Brinkschmidt C, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene. 2001;20:3835\u201344.","journal-title":"Oncogene"},{"key":"3572_CR133","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.3390\/cancers13102384","volume":"13","author":"D MacKenzie Jr.","year":"2021","unstructured":"MacKenzie D Jr., Watters AK, To JT, Young MW, Muratori J, Wilkoff MH, et al. ALT positivity in human cancers: prevalence and clinical insights. Cancers. 2021;13:2384.","journal-title":"Cancers"},{"key":"3572_CR134","doi-asserted-by":"publisher","unstructured":"Bennett D, Wierdl M,Chakraborty S, Johnson Jr JD, Akingbehin V, Estevez-Prado D, et al. Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers. bioRxiv 2026.03.04.709438; https:\/\/doi.org\/10.64898\/2026.03.04.709438","DOI":"10.64898\/2026.03.04.709438"},{"key":"3572_CR135","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/jnci\/djaf278","volume":"118","author":"M Rafati","year":"2026","unstructured":"Rafati M, Guenther LM, Egolf LE, Gianferante M, Kim J, Wang K, et al. SMARCAL1 is a new osteosarcoma predisposition gene. J Natl Cancer Inst. 2026;118:1120\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"3572_CR136","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1200\/JCO-25-01114","volume":"43","author":"N Oak","year":"2025","unstructured":"Oak N, Chen W, Blake A, Harrison L, O\u2019Brien M, Previti C, et al. Investigation of DNA damage response genes validates the role of DNA repair in pediatric cancer risk and identifies SMARCAL1 as a novel osteosarcoma predisposition gene. J Clin Oncol. 2025;43:3833\u201343.","journal-title":"J Clin Oncol"},{"key":"3572_CR137","doi-asserted-by":"crossref","unstructured":"Taglialatela A, Chen X, Khan ZF, Dela Cruz F, Shivi D, Oswald D, et al.: SMARCAL1 is a novel candidate therapeutic target for ALT-positive osteosarcoma. Can Res. 2024;84(1_Supplement):B023-B.","DOI":"10.1158\/1538-7445.DNAREPAIR24-B023"},{"key":"3572_CR138","doi-asserted-by":"crossref","unstructured":"Wierdl M, Catlett JL, Ocasio-Martinez N, Johnson JD, Jr., Herman A, et al. SMARCAL1 is a selective dependency and a novel synthetic lethal target in ATRX\/DAXX mutant ALT+ osteosarcoma and neuroblastoma. Can Res 2024;84(1_Supplement):PR004-PR.#","DOI":"10.1158\/1538-7445.DNAREPAIR24-PR004"},{"key":"3572_CR139","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1111\/febs.12867","volume":"281","author":"S Xie","year":"2014","unstructured":"Xie S, Lu Y, Jakoncic J, Sun H, Xia J, Qian C. Structure of RPA32 bound to the N-terminus of SMARCAL1 redefines the binding interface between RPA32 and its interacting proteins. FEBS J. 2014;281:3382\u201396.","journal-title":"FEBS J"},{"key":"3572_CR140","doi-asserted-by":"crossref","unstructured":"Mason AC, Rambo RP, Greer B, Pritchett M, Tainer JA, Cortez D, et al. A structure-specific nucleic acid-binding domain conserved among DNA repair proteins. Proc Natl Acad Sci USA. 2014;111:7618\u201323.","DOI":"10.1073\/pnas.1324143111"},{"key":"3572_CR141","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41586-024-07318-y","volume":"629","author":"KA Baltgalvis","year":"2024","unstructured":"Baltgalvis KA, Lamb KN, Symons KT, Wu CC, Hoffman MA, Snead AN, et al. Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase. Nature. 2024;629:435\u201342.","journal-title":"Nature"},{"key":"3572_CR142","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-024-07350-y","volume":"629","author":"S Ferretti","year":"2024","unstructured":"Ferretti S, Hamon J, de Kanter R, Scheufler C, Andraos-Rey R, Barbe S, et al. Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers. Nature. 2024;629:443\u20139.","journal-title":"Nature"},{"key":"3572_CR143","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71980","volume":"13","author":"SC Griffiths","year":"2024","unstructured":"Griffiths SC, Tan J, Wagner A, Blazer LL, Adams JJ, Srinivasan S, et al. Structure and function of the ROR2 cysteine-rich domain in vertebrate noncanonical WNT5A signaling. eLife. 2024;13:e71980.","journal-title":"eLife"},{"key":"3572_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.891763","volume":"10","author":"M Endo","year":"2022","unstructured":"Endo M, Kamizaki K, Minami Y. The Ror-family receptors in development, tissue regeneration and age-related disease. Front Cell Dev Biol. 2022;10:891763.","journal-title":"Front Cell Dev Biol"},{"key":"3572_CR145","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1083\/jcb.200607127","volume":"175","author":"M Nishita","year":"2006","unstructured":"Nishita M, Yoo SK, Nomachi A, Kani S, Sougawa N, Ohta Y, et al. Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration. J Cell Biol. 2006;175:555\u201362.","journal-title":"J Cell Biol"},{"key":"3572_CR146","doi-asserted-by":"publisher","first-page":"e1873","DOI":"10.1371\/journal.pone.0001873","volume":"3","author":"S Akbarzadeh","year":"2008","unstructured":"Akbarzadeh S, Wheldon LM, Sweet SM, Talma S, Mardakheh FK, Heath JK. The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src. PloS one. 2008;3:e1873.","journal-title":"PloS one"},{"key":"3572_CR147","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/gtc.12676","volume":"24","author":"M Weissenb\u00f6ck","year":"2019","unstructured":"Weissenb\u00f6ck M, Latham R, Nishita M, Wolff LI, Ho HH, Minami Y, et al. Genetic interactions between Ror2 and Wnt9a, Ror1 and Wnt9a and Ror2 and Ror1: phenotypic analysis ROR2 in osteosarcoma of the limb skeleton and palate in compound mutants. Genes Cells. 2019;24:307\u201317.","journal-title":"Genes Cells"},{"key":"3572_CR148","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1073\/pnas.1200421109","volume":"109","author":"HY Ho","year":"2012","unstructured":"Ho HY, Susman MW, Bikoff JB, Ryu YK, Jonas AM, Hu L, et al. Wnt5a-Ror-dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci USA. 2012;109:4044\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3572_CR149","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/gtc.12342","volume":"21","author":"X Qi","year":"2016","unstructured":"Qi X, Okinaka Y, Nishita M, Minami Y. Essential role of Wnt5a-Ror1\/Ror2 signaling in metanephric mesenchyme and ureteric bud formation. Genes Cells. 2016;21:325\u201334.","journal-title":"Genes Cells"},{"key":"3572_CR150","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1210\/me.2007-0323","volume":"21","author":"Y Liu","year":"2007","unstructured":"Liu Y, Ross JF, Bodine PV, Billiard J. Homodimerization of Ror2 tyrosine kinase receptor induces 14-3-3(beta) phosphorylation and promotes osteoblast differentiation and bone formation. Mol Endocrinol. 2007;21:3050\u201361.","journal-title":"Mol Endocrinol"},{"key":"3572_CR151","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/jcb.21848","volume":"105","author":"Y Liu","year":"2008","unstructured":"Liu Y, Rubin B, Bodine PV, Billiard J. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem. 2008;105:497\u2013502.","journal-title":"J Cell Biochem"},{"key":"3572_CR152","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2015.01.010","volume":"150","author":"Z Debebe","year":"2015","unstructured":"Debebe Z, Rathmell WK. Ror2 as a therapeutic target in cancer. Pharmacol Ther. 2015;150:143\u20138.","journal-title":"Pharmacol Ther"},{"key":"3572_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23074","volume":"34","author":"K Yang","year":"2020","unstructured":"Yang K, Zhu J, Tan Y, Sun X, Zhao H, Tang G, et al. Whole-exome sequencing identified compound heterozygous variants in ROR2 gene in a fetus with Robinow syndrome. J Clin Lab Anal. 2020;34:e23074.","journal-title":"J Clin Lab Anal"},{"key":"3572_CR154","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/dvdy.10466","volume":"229","author":"GC Schwabe","year":"2004","unstructured":"Schwabe GC, Trepczik B, S\u00fcring K, Brieske N, Tucker AS, Sharpe PT, et al. Ror2 knockout mouse as a model for the developmental pathology of autosomal recessive Robinow syndrome. Dev Dyn. 2004;229:400\u201310.","journal-title":"Dev Dyn"},{"key":"3572_CR155","doi-asserted-by":"publisher","first-page":"282","DOI":"10.14336\/AD.2023.0531","volume":"15","author":"Y Yao","year":"2024","unstructured":"Yao Y, Wang X, Lin L, Zhang X, Wang Y. ROR2-related skeletal dysplasia revealed disrupted chondrocyte polarity through modulation of BMP\/TGF-\u03b2 signaling. Aging Dis. 2024;15:282\u201394.","journal-title":"Aging Dis"},{"key":"3572_CR156","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.3892\/ol.2015.3797","volume":"10","author":"J Huang","year":"2015","unstructured":"Huang J, Shi Y, Li H, Tan D, Yang M, Wu X. Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression. Oncol Lett. 2015;10:3705\u201311.","journal-title":"Oncol Lett"},{"key":"3572_CR157","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3892\/mmr.2012.772","volume":"5","author":"BJ Lu","year":"2012","unstructured":"Lu BJ, Wang YQ, Wei XJ, Rong LQ, Wei D, Yan CM, et al. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep. 2012;5:1033\u20136.","journal-title":"Mol Med Rep"},{"key":"3572_CR158","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1349-7006.2009.01165.x","volume":"100","author":"K Morioka","year":"2009","unstructured":"Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, et al. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227\u201333.","journal-title":"Cancer Sci"},{"key":"3572_CR159","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-017-0482-y","volume":"17","author":"B Dai","year":"2017","unstructured":"Dai B, Yan T, Zhang A. ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a. Cancer Cell Int. 2017;17:112.","journal-title":"Cancer Cell Int"},{"key":"3572_CR160","first-page":"47","volume":"6","author":"Diem","year":"2020","unstructured":"Diem, Thi, Phuong, Takahiro T, Mongkol K, Kha P, et al. ROR2 regulates the survival of murine osteosarcoma cells in lung capillaries. J Cancer Metastasis Treat. 2020;6:47.","journal-title":"J Cancer Metastasis Treat"},{"key":"3572_CR161","doi-asserted-by":"crossref","unstructured":"Wong W, Adkins D, Misleh J, Lorch J, Grewal J, Russell J, et al. FPN: 868P. Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. European Society for Medical Oncology. Barcelona, Spain. September 13\u201317, 2024","DOI":"10.1016\/j.annonc.2024.08.929"},{"key":"3572_CR162","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrm3494","volume":"14","author":"EA Foley","year":"2013","unstructured":"Foley EA, Kapoor TM. Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore. Nat Rev Mol Cell Biol. 2013;14:25\u201337.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3572_CR163","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41586-020-03133-3","volume":"590","author":"RJ Quinton","year":"2021","unstructured":"Quinton RJ, DiDomizio A, Vittoria MA, Kot\u00fdnkov\u00e1 K, Ticas CJ, Patel S, et al. Whole genome doubling confers unique genetic vulnerabilities on tumour cells. Nature. 2021;590:492\u20137.","journal-title":"Nature"},{"key":"3572_CR164","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/s41467-021-21447-2","volume":"12","author":"C Marquis","year":"2021","unstructured":"Marquis C, Fonseca CL, Queen KA, Wood L, Vandal SE, Malaby HLH, et al. Chromosomally unstable tumor cells specifically require KIF18A for proliferation. Nat Comm. 2021;12:1213.","journal-title":"Nat Comm"},{"key":"3572_CR165","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41586-020-03114-6","volume":"590","author":"Y Cohen-Sharir","year":"2021","unstructured":"Cohen-Sharir Y, McFarland JM, Abdusamad M, Marquis C, Bernhard SV, Kazachkova M, et al. Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021;590:486\u201391.","journal-title":"Nature"},{"key":"3572_CR166","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/biom13020326","volume":"13","author":"T Liu","year":"2023","unstructured":"Liu T, Yang K, Chen J, Qi L, Zhou X, Wang P. Comprehensive pan-cancer analysis of KIF18A as a marker for prognosis and immunity. Biomolecules. 2023;13:2.","journal-title":"Biomolecules"},{"key":"3572_CR167","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.devcel.2007.11.014","volume":"14","author":"J Stumpff","year":"2008","unstructured":"Stumpff J, von Dassow G, Wagenbach M, Asbury C, Wordeman L. The kinesin-8 motor Kif18A suppresses kinetochore movements to control mitotic chromosome alignment. Dev Cell. 2008;14:252\u201362.","journal-title":"Dev Cell"},{"key":"3572_CR168","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cub.2007.02.036","volume":"17","author":"MI Mayr","year":"2007","unstructured":"Mayr MI, H\u00fcmmer S, Bormann J, Gr\u00fcner T, Adio S, Woehlke G, et al. The human kinesin Kif18A is a motile microtubule depolymerase essential for chromosome congression. Curr Biol. 2007;17:488\u201398.","journal-title":"Curr Biol"},{"key":"3572_CR169","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1083\/jcb.201807228","volume":"218","author":"CL Fonseca","year":"2019","unstructured":"Fonseca CL, Malaby HLH, Sepaniac LA, Martin W, Byers C, Czechanski A, et al. Mitotic chromosome alignment ensures mitotic fidelity by promoting interchromosomal compaction during anaphase. J Cell Biol. 2019;218:1148\u201363.","journal-title":"J Cell Biol"},{"key":"3572_CR170","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ydbio.2015.03.011","volume":"402","author":"A Czechanski","year":"2015","unstructured":"Czechanski A, Kim H, Byers C, Greenstein I, Stumpff J, Reinholdt LG. Kif18a is specifically required for mitotic progression during germ line development. Dev Biol. 2015;402:253\u201362.","journal-title":"Dev Biol"},{"key":"3572_CR171","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1177\/1947601909358184","volume":"1","author":"XS Liu","year":"2010","unstructured":"Liu XS, Zhao XD, Wang X, Yao YX, Zhang LL, Shu RZ, et al. Germinal cell aplasia in Kif18a mutant male mice due to impaired chromosome congression and dysregulated BubR1 and CENP-E. Genes Cancer. 2010;1:26\u201339.","journal-title":"Genes Cancer"},{"key":"3572_CR172","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.mod.2006.05.003","volume":"123","author":"LG Reinholdt","year":"2006","unstructured":"Reinholdt LG, Munroe RJ, Kamdar S, Schimenti JC. The mouse gcd2 mutation causes primordial germ cell depletion. Mech Dev. 2006;123:559\u201369.","journal-title":"Mech Dev"},{"key":"3572_CR173","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10555-024-10225-3","volume":"44","author":"AS Mohd Amin","year":"2024","unstructured":"Mohd Amin AS, Eastwood S, Pilcher C, Truong JQ, Foitzik R, Boag J, et al. KIF18A inhibition: the next big player in the search for cancer therapeutics. Cancer Metastasis Rev. 2024;44:3.","journal-title":"Cancer Metastasis Rev"},{"key":"3572_CR174","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1021\/acs.jmedchem.1c02030","volume":"65","author":"NA Tamayo","year":"2022","unstructured":"Tamayo NA, Bourbeau MP, Allen JR, Ashton KS, Chen JJ, Kaller MR, et al. Targeting the mitotic kinesin KIF18A in chromosomally unstable cancers: hit optimization toward an in vivo chemical probe. J Med Chem. 2022;65:4972\u201390.","journal-title":"J Med Chem"},{"key":"3572_CR175","doi-asserted-by":"crossref","unstructured":"Belmontes B, Moriguchi J, Chung G, Sun J, Ninniri MSS, Hanestad K, et al. Discovery and preclinical characterization of AMG 650, a first-in-class inhibitor of kinesin KIF18A motor protein with potent activity against chromosomally unstable cancers [abstract]. Cancer Res 2023;83(7_Suppl):Abstract nr 516","DOI":"10.1158\/1538-7445.AM2023-516"},{"key":"3572_CR176","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00432-018-2710-9","volume":"144","author":"J Schiewek","year":"2018","unstructured":"Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, et al. Clinical relevance of cytoskeleton-associated proteins for ovarian cancer. J. Cancer Res. Clin. Oncol. 2018;144:2195\u2013205.","journal-title":"J. Cancer Res. Clin. Oncol"},{"key":"3572_CR177","doi-asserted-by":"publisher","first-page":"a032607","DOI":"10.1101\/cshperspect.a032607","volume":"11","author":"JWB Hershey","year":"2019","unstructured":"Hershey JWB, Sonenberg N, Mathews MB. Principles of translational control. Cold Spring Harb Perspect Biol. 2019;11:a032607.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3572_CR178","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/path.5030","volume":"244","author":"AM El-Naggar","year":"2018","unstructured":"El-Naggar AM, Sorensen PH. Translational control of aberrant stress responses as a hallmark of cancer. J Pathol. 2018;244:650\u201366.","journal-title":"J Pathol"},{"key":"3572_CR179","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1158\/1078-0432.CCR-24-1317","volume":"30","author":"MM Lizardo","year":"2024","unstructured":"Lizardo MM, Hughes C, Huang YZ, Shyp T, Delaidelli A, Zhang HF, et al. Pharmacologic inhibition of EIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis. Clin Cancer Res. 2024;30:4464\u201381.","journal-title":"Clin Cancer Res"},{"key":"3572_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1158775","volume":"14","author":"Z Lin","year":"2023","unstructured":"Lin Z, Wu Z, Yuan Y, Zhong W, Luo W. m7G-related genes predict prognosis and affect the immune microenvironment and drug sensitivity in osteosarcoma. Front Pharmacol. 2023;14:1158775.","journal-title":"Front Pharmacol"},{"key":"3572_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69171-3","volume":"14","author":"JL Oblinger","year":"2024","unstructured":"Oblinger JL, Wang J, Wetherell GD, Agarwal G, Wilson TA, Benson NR, et al. Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas. Sci Rep. 2024;14:19349.","journal-title":"Sci Rep"},{"key":"3572_CR182","doi-asserted-by":"crossref","unstructured":"Zhao Y, Li T, Tian S, Meng W, Sui Y, Yang J, et al. Effective inhibition of MYC-amplified group 3 medulloblastoma through targeting EIF4A1. Cancer Manag Res. 2020;12:12473\u201385.","DOI":"10.2147\/CMAR.S278844"},{"key":"3572_CR183","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1021\/jo040120f","volume":"69","author":"BY Hwang","year":"2004","unstructured":"Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, Afriastini JJ, et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem. 2004;69:3350\u20138.","journal-title":"J Org Chem"},{"key":"3572_CR184","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bmc.2013.11.046","volume":"22","author":"WK Low","year":"2014","unstructured":"Low WK, Li J, Zhu M, Kommaraju SS, Shah-Mittal J, Hull K, et al. Second-generation derivatives of the eukaryotic translation initiation inhibitor pateamine A targeting eIF4A as potential anticancer agents. Bioorg Med Chem. 2014;22:116\u201325.","journal-title":"Bioorg Med Chem"},{"key":"3572_CR185","doi-asserted-by":"publisher","first-page":"12891","DOI":"10.1021\/jacs.9b06446","volume":"141","author":"W Zhang","year":"2019","unstructured":"Zhang W, Chu J, Cyr AM, Yueh H, Brown LE, Wang TT, et al. Intercepted retro-nazarov reaction: syntheses of amidino-rocaglate derivatives and their biological evaluation as eIF4A inhibitors. J Am Chem Soc. 2019;141:12891\u2013900.","journal-title":"J Am Chem Soc"},{"key":"3572_CR186","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.chembiol.2019.08.008","volume":"26","author":"J Chu","year":"2019","unstructured":"Chu J, Zhang W, Cencic R, Devine WG, Beglov D, Henkel T, et al. Amidino-rocaglates: a potent class of eIF4A inhibitors. Cell Chem Biol. 2019;26:1586\u201393.e3.","journal-title":"Cell Chem Biol"},{"key":"3572_CR187","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chembiol.2020.11.008","volume":"28","author":"M Chen","year":"2021","unstructured":"Chen M, Asanuma M, Takahashi M, Shichino Y, Mito M, Fujiwara K, et al. Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A. Cell Chem Biol. 2021;28:475\u201386.e8.","journal-title":"Cell Chem Biol"},{"key":"3572_CR188","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1021\/acs.jmedchem.0c00182","volume":"63","author":"JT Ernst","year":"2020","unstructured":"Ernst JT, Thompson PA, Nilewski C, Sprengeler PA, Sperry S, Packard G, et al. Design of development candidate eFT226, a first in class inhibitor of eukaryotic initiation factor 4A RNA helicase. J Med Chem. 2020;63:5879\u2013955.","journal-title":"J Med Chem"},{"key":"3572_CR189","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2318093121","volume":"121","author":"R Cencic","year":"2024","unstructured":"Cencic R, Im YK, Naineni SK, Moustafa-Kamal M, Jovanovic P, Sabourin V, et al. A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer. Proc Natl Acad Sci USA. 2024;121:e2318093121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3572_CR190","doi-asserted-by":"publisher","first-page":"S372","DOI":"10.1016\/j.annonc.2024.08.315","volume":"35","author":"E Rosen","year":"2024","unstructured":"Rosen E, Caswell-Jin J, Berz D, Mai N, Fulgar G, Densel M, et al. 367P Phase I\/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer. Ann Oncol. 2024;35:S372.","journal-title":"Ann Oncol"},{"key":"3572_CR191","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/ng0797-307","volume":"16","author":"B Lee","year":"1997","unstructured":"Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, et al. Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2\/CBFA1 incleidocranial dysplasia. Nat Genet. 1997;16:307\u201310.","journal-title":"Nat Genet"},{"key":"3572_CR192","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0092-8674(00)80259-7","volume":"89","author":"F Otto","year":"1997","unstructured":"Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89:765\u201371.","journal-title":"Cell"},{"key":"3572_CR193","doi-asserted-by":"publisher","first-page":"8650","DOI":"10.1073\/pnas.151236498","volume":"98","author":"JY Choi","year":"2001","unstructured":"Choi JY, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, et al. Subnuclear targeting of Runx\/Cbfa\/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA. 2001;98:8650\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3572_CR194","doi-asserted-by":"publisher","first-page":"20274","DOI":"10.1074\/jbc.M413665200","volume":"280","author":"M Galindo","year":"2005","unstructured":"Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, et al. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem. 2005;280:20274\u201385.","journal-title":"J Biol Chem"},{"key":"3572_CR195","first-page":"5357","volume":"63","author":"J Pratap","year":"2003","unstructured":"Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Can Res. 2003;63:5357\u201362.","journal-title":"Can Res"},{"key":"3572_CR196","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0092-8674(00)80257-3","volume":"89","author":"P Ducy","year":"1997","unstructured":"Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2\/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747\u201354.","journal-title":"Cell"},{"key":"3572_CR197","doi-asserted-by":"publisher","first-page":"7101","DOI":"10.1074\/jbc.M006215200","volume":"276","author":"B Kern","year":"2001","unstructured":"Kern B, Shen J, Starbuck M, Karsenty G. Cbfa1 contributes to the osteoblast-specific expression of type I collagen genes. J Biol Chem. 2001;276:7101\u20137.","journal-title":"J Biol Chem"},{"key":"3572_CR198","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/03008200390152188","volume":"44","author":"RT Franceschi","year":"2003","unstructured":"Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E. Multiple signaling pathways converge on the Cbfa1\/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res. 2003;44:109\u201316. Suppl 1(Suppl 1).","journal-title":"Connect Tissue Res"},{"key":"3572_CR199","first-page":"4506","volume":"64","author":"GL Barnes","year":"2004","unstructured":"Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, et al. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. CanRes. 2004;64:4506\u201313.","journal-title":"CanRes"},{"key":"3572_CR200","doi-asserted-by":"publisher","first-page":"7795","DOI":"10.1158\/0008-5472.CAN-08-1078","volume":"68","author":"J Pratap","year":"2008","unstructured":"Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, et al. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Can Res. 2008;68:7795\u2013802.","journal-title":"Can Res"},{"key":"3572_CR201","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11033-008-9378-1","volume":"36","author":"SS Nathan","year":"2009","unstructured":"Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C, Soong R, et al. Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep. 2009;36:153\u20138.","journal-title":"Mol Biol Rep"},{"key":"3572_CR202","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/jcp.21894","volume":"221","author":"IA San Martin","year":"2009","unstructured":"San Martin IA, Varela N, Gaete M, Villegas K, Osorio M, Tapia JC, et al. Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells. J Cell Physiol. 2009;221:560\u201371.","journal-title":"J Cell Physiol"},{"key":"3572_CR203","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-202","volume":"10","author":"B Sadikovic","year":"2010","unstructured":"Sadikovic B, Thorner P, Chilton-Macneill S, Martin JW, Cervigne NK, Squire J, et al. Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer. 2010;10:202.","journal-title":"BMC Cancer"},{"key":"3572_CR204","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/030089160909500307","volume":"95","author":"KY Won","year":"2009","unstructured":"Won KY, Park HR, Park YK. Prognostic implication of immunohistochemical Runx2 expression in osteosarcoma. Tumori. 2009;95:311\u20136.","journal-title":"Tumori"},{"key":"3572_CR205","volume":"6","author":"J Yang","year":"2013","unstructured":"Yang J, Zhao L, Tian W, Liao Z, Zheng H, Wang G, et al. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med Genet. 2013;6:56.","journal-title":"BMC Med Genet"},{"key":"3572_CR206","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/gcc.10291","volume":"39","author":"CC Lau","year":"2004","unstructured":"Lau CC, Harris CP, Lu XY, Perlaky L, Gogineni S, Chintagumpala M, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer. 2004;39:11\u201321.","journal-title":"Genes Chromosomes Cancer"},{"key":"3572_CR207","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3892\/ol.2015.3124","volume":"9","author":"H Zeng","year":"2015","unstructured":"Zeng H, Xu X. RUNX2 RNA interference inhibits the invasion of osteosarcoma. Oncol Lett. 2015;9:2455\u20138.","journal-title":"Oncol Lett"},{"key":"3572_CR208","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/bjc.2015.305","volume":"113","author":"A Roos","year":"2015","unstructured":"Roos A, Satterfield L, Zhao S, Fuja D, Shuck R, Hicks MJ, et al. Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis. Br J Cancer. 2015;113:1289\u201397.","journal-title":"Br J Cancer"},{"key":"3572_CR209","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jcp.24218","volume":"228","author":"CM Lucero","year":"2013","unstructured":"Lucero CM, Vega OA, Osorio MM, Tapia JC, Antonelli M, Stein GS, et al. The cancer related transcription factor Runx2 modulates cell proliferation in human osteosarcoma cell lines. J Cell Physiol. 2013;228:714\u201323.","journal-title":"J Cell Physiol"},{"key":"3572_CR210","doi-asserted-by":"publisher","first-page":"19861","DOI":"10.1073\/pnas.0709650104","volume":"104","author":"SK Zaidi","year":"2007","unstructured":"Zaidi SK, Pande S, Pratap J, Gaur T, Grigoriu S, Ali SA, et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc Natl Acad Sci USA. 2007;104:19861\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3572_CR211","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/282745","volume":"2011","author":"JW Martin","year":"2011","unstructured":"Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA. The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma. 2011;2011:282745.","journal-title":"Sarcoma"},{"key":"3572_CR212","doi-asserted-by":"publisher","first-page":"36181","DOI":"10.1074\/jbc.M206057200","volume":"277","author":"G Xiao","year":"2002","unstructured":"Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1\/Runx2. J Biol Chem. 2002;277:36181\u20137.","journal-title":"J Biol Chem"},{"key":"3572_CR213","doi-asserted-by":"publisher","first-page":"42709","DOI":"10.1074\/jbc.M404480200","volume":"279","author":"M Qiao","year":"2004","unstructured":"Qiao M, Shapiro P, Kumar R, Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase\/ERK-dependent and Akt-independent signaling pathway. J Biol Chem. 2004;279:42709\u201318.","journal-title":"J Biol Chem"},{"key":"3572_CR214","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.127","volume":"4","author":"T Ozaki","year":"2013","unstructured":"Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis. 2013;4:e610.","journal-title":"Cell Death Dis"},{"key":"3572_CR215","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0404-3","volume":"14","author":"KA Cohen-Solal","year":"2015","unstructured":"Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K\/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14:137.","journal-title":"Mol Cancer"},{"key":"3572_CR216","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1074\/jbc.M111.287771","volume":"287","author":"M van der Deen","year":"2012","unstructured":"van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA, et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem. 2012;287:4503\u201317.","journal-title":"J Biol Chem"},{"key":"3572_CR217","doi-asserted-by":"publisher","first-page":"48684","DOI":"10.1074\/jbc.M308001200","volume":"278","author":"CK Inman","year":"2003","unstructured":"Inman CK, Shore P. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem. 2003;278:48684\u20139.","journal-title":"J Biol Chem"},{"key":"3572_CR218","doi-asserted-by":"publisher","first-page":"13659","DOI":"10.1002\/jcp.28046","volume":"234","author":"F Villanueva","year":"2019","unstructured":"Villanueva F, Araya H, Brice\u00f1o P, Varela N, Stevenson A, Jerez S, et al. The cancer related transcription factor RUNX2 modulates expression and secretion of the matricellular RUNX2 in osteosarcoma protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. J Cell Physiol. 2019;234:13659\u201379.","journal-title":"J Cell Physiol"},{"key":"3572_CR219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100474","volume":"39","author":"D Green","year":"2023","unstructured":"Green D, Singh A, Tippett VL, Tattersall L, Shah KM, Siachisumo C, et al. YBX1-interacting small RNAs and RUNX2 can be blocked in primary bone cancer using CADD522. J Bone Oncol. 2023;39:100474.","journal-title":"J Bone Oncol"},{"key":"3572_CR220","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.18632\/oncotarget.27743","volume":"11","author":"MS Kim","year":"2020","unstructured":"Kim MS, Gernapudi R, Cede\u00f1o YC, Polster BM, Martinez R, Shapiro P, et al. Targeting breast cancer metabolism with a novel inhibitor of mitochondrial ATP synthesis. Oncotarget. 2020;11:3863\u201385.","journal-title":"Oncotarget"},{"key":"3572_CR221","doi-asserted-by":"publisher","first-page":"70916","DOI":"10.18632\/oncotarget.20200","volume":"8","author":"MS Kim","year":"2017","unstructured":"Kim MS, Gernapudi R, Choi EY, Lapidus RG, Passaniti A. Characterization of CADD522, a small molecule that inhibits RUNX2-DNA binding and exhibits antitumor activity. Oncotarget. 2017;8:70916\u201340.","journal-title":"Oncotarget"},{"key":"3572_CR222","doi-asserted-by":"publisher","unstructured":"Mendes EA, Munshi A, Singh A, et al. RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma. bioRxiv. 2025;2025.07.21.665972. https:\/\/doi.org\/10.1101\/2025.07.21.665972","DOI":"10.1101\/2025.07.21.665972"},{"key":"3572_CR223","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-018-0560-1","volume":"11","author":"B Zheng","year":"2018","unstructured":"Zheng B, Ren T, Huang Y, Sun K, Wang S, Bao X, et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16.","journal-title":"J Hematol Oncol"},{"key":"3572_CR224","doi-asserted-by":"crossref","unstructured":"Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015;3:21.","DOI":"10.1186\/s40425-015-0067-z"},{"key":"3572_CR225","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493\u2013501.","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"3572_CR226","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","volume":"70","author":"K Boye","year":"2021","unstructured":"Boye K, Longhi A, Guren T, Lorenz S, N\u00e6ss S, Pierini M, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021;70:2617\u201324.","journal-title":"Cancer Immunol Immunother"},{"key":"3572_CR227","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","volume":"28","author":"A Italiano","year":"2022","unstructured":"Italiano A, Bessede A, Pulido M, Bompas E, Piperno-Neumann S, Chevreau C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nat Med. 2022;28:1199\u2013206.","journal-title":"Nat Med"},{"key":"3572_CR228","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","volume":"21","author":"KL Davis","year":"2020","unstructured":"Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020;21:541\u201350.","journal-title":"Lancet Oncol"},{"key":"3572_CR229","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","volume":"28","author":"KL Davis","year":"2022","unstructured":"Davis KL, Fox E, Isikwei E, Reid JM, Liu X, Minard CG, et al. A Phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: a Children\u2019s Oncology Group Study ADVL1412. Clin Cancer Res. 2022;28:5088\u201397.","journal-title":"Clin Cancer Res"},{"key":"3572_CR230","doi-asserted-by":"publisher","first-page":"e0189697","DOI":"10.1371\/journal.pone.0189697","volume":"12","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y, Yasui T, Tamari K, Minami K, Otani K, Isohashi F, et al. Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PloS one. 2017;12:e0189697.","journal-title":"PloS one"},{"key":"3572_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2023.100675","volume":"20","author":"D Xiang","year":"2023","unstructured":"Xiang D, Han X, Li J, Zhang J, Xiao H, Li T, et al. Combination of IDO inhibitors and platinum(IV) prodrugs reverses low immune responses to enhance cancer chemotherapy and immunotherapy for osteosarcoma. Mater Today Bio. 2023;20:100675.","journal-title":"Mater Today Bio"},{"key":"3572_CR232","doi-asserted-by":"crossref","unstructured":"Young EP, Johnson CA, Lee AG, Morris D, Tsui J, Breese MR, et al. STING activation reshapes the tumor microenvironment leading to tumor regression in osteosarcoma. bioRxiv [Preprint]. 2025:2025.10.24.684275.","DOI":"10.1101\/2025.10.24.684275"},{"key":"3572_CR233","doi-asserted-by":"publisher","first-page":"e70689","DOI":"10.1371\/journal.pone.0070689","volume":"8","author":"L Wang","year":"2013","unstructured":"Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, et al. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PloS one. 2013;8:e70689.","journal-title":"PloS one"},{"key":"3572_CR234","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1158\/2767-9764.CRC-25-0086","volume":"5","author":"M Choe","year":"2025","unstructured":"Choe M, Kirkey D, Lira I, et al. Preclinical evaluation of folate receptor-\u03b1 chimeric antigen receptor T cells exhibits highly efficient antitumor activity against osteosarcoma. Cancer Res Commun. 2025;5:1701\u201313.","journal-title":"Cancer Res Commun"},{"key":"3572_CR235","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.28461","volume":"120","author":"M Roth","year":"2014","unstructured":"Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120:548\u201354.","journal-title":"Cancer"},{"key":"3572_CR236","doi-asserted-by":"crossref","unstructured":"Xie L, Xu J, Sun X, Liang X, Liu K, Yang Y, et al. ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. J Clin Oncol. 2024;42:11507.","DOI":"10.1200\/JCO.2024.42.16_suppl.11507"},{"key":"3572_CR237","doi-asserted-by":"crossref","unstructured":"Xie L, Shen J, Xu J, Sun X,. Ji T, Hu H, et al. 2684O ARTEMIS-002: a phase II study of HS-20093 in patients with relapsed or refractory sarcomas. Ann. Oncol. 2025. 36S1337","DOI":"10.1016\/j.annonc.2025.08.3295"},{"key":"3572_CR238","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.3390\/cancers13112796","volume":"13","author":"AE Quamine","year":"2021","unstructured":"Quamine AE, Olsen MR, Cho MM, Capitini CM. Approaches to enhance natural killer cell-based immunotherapy for pediatric solid tumors. Cancers. 2021;13:2796.","journal-title":"Cancers"},{"key":"3572_CR239","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353.","journal-title":"Nat Biotechnol"},{"key":"3572_CR240","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s11999-012-2299-2","volume":"470","author":"M Kawano","year":"2012","unstructured":"Kawano M, Itonaga I, Iwasaki T, Tsuchiya H, Tsumura H. Anti-TGF-\u03b2 antibody combined with dendritic cells produce antitumor effects in osteosarcoma. Clin Orthop Relat Res. 2012;470:2288\u201394.","journal-title":"Clin Orthop Relat Res"},{"key":"3572_CR241","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3892\/or.2015.4161","volume":"34","author":"M Kawano","year":"2015","unstructured":"Kawano M, Tanaka K, Itonaga I, Iwasaki T, Miyazaki M, Ikeda S, et al. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. Oncol Rep. 2015;34:1995\u20132001.","journal-title":"Oncol Rep"},{"key":"3572_CR242","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23:192.","journal-title":"Mol Cancer"},{"key":"3572_CR243","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/cjp2.219","volume":"7","author":"S De Noon","year":"2021","unstructured":"De Noon S, Ijaz J, Coorens TH, Amary F, Ye H, Strobl A, et al. MYC amplifications are common events in childhood osteosarcoma. J Pathol Clin Res. 2021;7:425\u201331.","journal-title":"J Pathol Clin Res"},{"key":"3572_CR244","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00334","volume":"7","author":"AE Marinoff","year":"2023","unstructured":"Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, et al. Clinical targeted next-generation panel sequencing reveals MYC amplification is a poor prognostic factor in osteosarcoma. JCO Precis Oncol. 2023;7:e2200334.","journal-title":"JCO Precis Oncol"},{"key":"3572_CR245","doi-asserted-by":"crossref","unstructured":"Duffy MJ, Tang M, Crown J. MYC as a target for cancer treatment: from undruggable to druggable? TargetOncol. 2025;20:791\u2013801.","DOI":"10.1007\/s11523-025-01169-x"},{"key":"3572_CR246","doi-asserted-by":"crossref","unstructured":"Masso-Valles D, Soucek L. Blocking Myc to treat cancer: reflecting on two decades of Omomyc. Cells. 2020. 883","DOI":"10.3390\/cells9040883"},{"key":"3572_CR247","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","volume":"30","author":"E Garralda","year":"2024","unstructured":"Garralda E, Beaulieu ME, Moreno V, Casacuberta-Serra S, Mart\u00ednez-Mart\u00edn S, et al. MYC targeting by OMO-103 in solid tumors: a phase 1 trial. Nat Med. 2024;30:762\u201371.","journal-title":"Nat Med"},{"key":"3572_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109013","volume":"35","author":"B Veo","year":"2021","unstructured":"Veo B, Danis E, Pierce A, Wang D, Fosmire S, Sullivan KD, et al. Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in MYC-driven medulloblastoma. Cell Rep. 2021;35:109013.","journal-title":"Cell Rep"},{"key":"3572_CR249","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1111\/febs.16580","volume":"290","author":"A Kotekar","year":"2023","unstructured":"Kotekar A, Singh AK, Devaiah BN. BRD4 and MYC: power couple in transcription and disease. FEBS J. 2023;290:4820\u201342.","journal-title":"FEBS J"},{"key":"3572_CR250","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/neuonc\/noaf121","volume":"27","author":"LM Sobral","year":"2025","unstructured":"Sobral LM, Walker FM, Madhavan K, Janko E, Donthula S, Danis E, et al. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025;27:2697\u2013710.","journal-title":"Neuro Oncol"},{"key":"3572_CR251","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13046-023-02790-2","volume":"42","author":"C Pitolli","year":"2023","unstructured":"Pitolli C, Marini A, Guerra M, Pieraccioli M, Marabitti V, Palluzzi F, et al. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. J Exp Clin Cancer Res. 2023;42:214.","journal-title":"J Exp Clin Cancer Res"},{"key":"3572_CR252","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ccr.2014.07.015","volume":"26","author":"WC Gustafson","year":"2014","unstructured":"Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014;26:414\u201327.","journal-title":"Cancer Cell"},{"key":"3572_CR253","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118252","volume":"258","author":"S Jiang","year":"2020","unstructured":"Jiang S, Awadasseid A, Narva S, Cao S, Tanaka Y, Wu Y, et al. Anti-cancer activity of benzoxazinone derivatives via targeting c-Myc G-quadruplex structure. Life Sci. 2020;258:118252.","journal-title":"Life Sci"},{"key":"3572_CR254","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.2147\/OTT.S210575","volume":"12","author":"H Mo","year":"2019","unstructured":"Mo H, He J, Yuan Z, Wu Z, Liu B, Lin X, et al. PLK1 contributes to autophagy by regulating MYC stabilization in osteosarcoma cells. Onco Targets Ther. 2019;12:7527\u201336.","journal-title":"Onco Targets Ther"},{"key":"3572_CR255","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/sj.bjc.6605014","volume":"100","author":"PF Ambros","year":"2009","unstructured":"Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100:1471\u201382.","journal-title":"Br J Cancer"},{"key":"3572_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112950","volume":"190","author":"ADJ Pearson","year":"2023","unstructured":"Pearson ADJ, Federico S, Gatz SA, Ortiz M, Lesa G, Scobie N, et al. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2023;190:112950.","journal-title":"Eur J Cancer"},{"key":"3572_CR257","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.1200\/JCO.2025.43.16_suppl.10005","volume":"43","author":"SJ Forrest","year":"2025","unstructured":"Forrest SJ, Livingston JA, Vo KT, Glade Bender JL, Opara A, Smith S, et al. Results of a phase II trial of olaparib in combination with ceralasertib in patients with recurrent and unresectable osteosarcoma. J Clin Oncol. 2025;43:10005\u201310005. (16_suppl).","journal-title":"J Clin Oncol"},{"key":"3572_CR258","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap TA, Fontana E, Lee EK, Spigel DR, H\u00f8jgaard M, Lheureux S, et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023;29:1400\u201311.","journal-title":"Nat Med"},{"key":"3572_CR259","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/jnci\/djae098","volume":"116","author":"E Fontana","year":"2024","unstructured":"Fontana E, Rosen E, Lee EK, H\u00f8jgaard M, Mettu NB, Lheureux S, et al. Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study). J Natl Cancer Inst. 2024;116:1439\u201349.","journal-title":"J Natl Cancer Inst"},{"key":"3572_CR260","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap TA, Tolcher AW, Plummer R, Mukker JK, Enderlin M, Hicking C, et al. First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res. 2024;30:2057\u201367.","journal-title":"Clin Cancer Res"},{"key":"3572_CR261","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1158\/2159-8290.CD-24-1500","volume":"15","author":"TA Yap","year":"2025","unstructured":"Yap TA, Tan DSP, Stathis A, Shapiro GI, Iwasa S, Joerger M, et al. Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects. Cancer Discov. 2025;15:2019\u201335.","journal-title":"Cancer Discov"},{"key":"3572_CR262","doi-asserted-by":"crossref","unstructured":"Doz F, Andre N, Guerra-Garc\u0131a P, Juan-Ribelles A, Mora J, Moreno L, et al. Safety and PK (pharmacokinetic) profile of niraparib (nir) + dostarlimab (dost) in pediatric patients (pts) with recurrent or refractory (RR) solid tumors: SCOOP study. J Oncol. 2023;41:10040.","DOI":"10.1200\/JCO.2023.41.16_suppl.10040"},{"key":"3572_CR263","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27291-8","volume":"12","author":"G Zoumpoulidou","year":"2021","unstructured":"Zoumpoulidou G, Alvarez-Mendoza C, Mancusi C, Ahmed RM, Denman M, Steele CD, et al. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nat Commun. 2021;12:7064.","journal-title":"Nat Commun"},{"key":"3572_CR264","doi-asserted-by":"publisher","first-page":"9176","DOI":"10.3390\/ijms21239176","volume":"21","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Yam JC, Tham CC, Pang CP, Chu WK. RB regulates DNA double strand break repair pathway choice by mediating CtIP dependent end resection. Int J Mol Sci. 2020;21:9176.","journal-title":"Int J Mol Sci"},{"key":"3572_CR265","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq9495","volume":"11","author":"J Iacovacci","year":"2025","unstructured":"Iacovacci J, Brough R, Moughari FA, Alexander J, Kemp H, Tutt ANJ, et al. Proteogenomic discovery of RB1-defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets. Sci Adv. 2025;11:eadq9495.","journal-title":"Sci Adv"},{"key":"3572_CR266","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165268","volume":"8","author":"Q Dong","year":"2023","unstructured":"Dong Q, Yu T, Chen B, Liu M, Sun X, Cao H, et al. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS\/STING pathway. JCI Insight. 2023;8:e165268.","journal-title":"JCI Insight"},{"key":"3572_CR267","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202302067","volume":"6","author":"LG Zamalloa","year":"2023","unstructured":"Zamalloa LG, Pruitt MM, Hermance NM, Gali H, Flynn RL, Manning AL. RB loss sensitizes cells to replication-associated DNA damage after PARP inhibition by trapping. Life Sci Alliance. 2023;6:e20230206.","journal-title":"Life Sci Alliance"},{"key":"3572_CR268","doi-asserted-by":"publisher","first-page":"10687","DOI":"10.3390\/ijms221910687","volume":"22","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Yam JC, Chu WK. Poly ADP ribose polymerase inhibitor olaparib targeting microhomology end joining in retinoblastoma protein defective cancer: analysis of the retinoblastoma cell-killing effects by olaparib after inducing double-strand breaks. Int J Mol Sci. 2021;22:10687.","journal-title":"Int J Mol Sci"},{"key":"3572_CR269","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/1538-7445.AM2024-3912","volume":"84","author":"SN Kocinsky","year":"2024","unstructured":"Kocinsky SN, Morsby JJ, WrighT WC, Wierdl M, Wechsler CS, Alexe G, et al. ATM and PARP combined inhibition demonstrate synergistic antitumor efficacy in osteosarcoma models. Cancer Res. 2024;84:3912.","journal-title":"Cancer Res"},{"key":"3572_CR270","doi-asserted-by":"crossref","unstructured":"Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the Children\u2019s Oncology Group. J Cin Oncol. l2012;30:2545-51.","DOI":"10.1200\/JCO.2011.37.4546"},{"key":"3572_CR271","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/mt.2009.133","volume":"17","author":"N Ahmed","year":"2009","unstructured":"Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009;17:1779\u201387.","journal-title":"Mol Ther"},{"key":"3572_CR272","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33:1688\u201396.","journal-title":"J Clin Oncol"},{"key":"3572_CR273","first-page":"3034","volume":"39","author":"R Jin","year":"2018","unstructured":"Jin R, Jin YY, Tang YL, Yang HJ, Zhou XQ, Lei Z. GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K\/Akt\/mTOR signaling pathway. Oncol Rep. 2018;39:3034\u201340.","journal-title":"Oncol Rep"},{"key":"3572_CR274","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ejca.2019.08.015","volume":"121","author":"LM Kopp","year":"2019","unstructured":"Kopp LM, Malempati S, Krailo M, Gao Y, Buxton A, Weigel BJ, et al. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the Children\u2019s Oncology Group. Eur J Can. 2019;121:177\u201383.","journal-title":"Eur J Can"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03572-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:02:14Z","timestamp":1787068934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03572-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":274,"alternative-id":["3572"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03572-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"7 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EP has served on advisory boards for Daiichy Sankyo, Deciphera Pharmaceuticals, Eusa Pharma, and SynOx Therapeutics, Ipsen Biopharmaceuticals, Springworks, Servier, and EDM Serono. NG through ITCC as participated had an advisory role as well as PI of industry-sponsor trial (EISAI, IPSEN). PB has a consulting role (institutional) for Recordati\/EUSA Pharma and EDM Serono; participated in educational activities (institutional) organised by Recordati\/EUSA Pharma and obtained institutional funding and drug for trials from Bayer. MM has served on advisory boards for Amgen, Ipsen and Medannex. DR has none related to this work but has served on advisory boards for Recordati and Eisai and data and safety monitoring committee for Springworks. SJS has served on advisory boards for Ipsen Biopharmaceuticals. Bayer, Tessellate Bio, Inhibrx and Serb Pharmaceuticals. CV has served on advisory boards for Deciphera Pharmaceuticals, PharmaMar, Cogent, Lilly, Boehringer Ingelheim, Mundipharma and Springworks; obtained institutional funding and drugs for trials from Peptomycs (OMO-103), Pfizer, PharmaMar, Bayer, Roche, Mundipharma, Boehringer Ingelheim, GSK, Lilly, Adaptimmune, Karyopharm, Foghorn Therapeutics, Inhibrx, Servier Bio-Innovation, iOMX Therapeutics. JSB, CME, GL, MK, SeP, MW, GW and DJ are employees of LifeArc. ADJP is a consultant for LifeArc. All other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}